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1.Introduction 
The steroid hormones are lipophilic compounds with low molecular weight, derived from 
cholesterol, which play a crucial role in differentiation, development and physiological 
functions of many tissues. They are synthesized primarily by endocrine glands, such as the 
gonads, the adrenal glands and the feto-placental unit during pregnancy. In addition, the 
central nervous system (CNS) seems to be able to synthesize a number of biologically active 
steroids, termed “neurosteroids”, with autocrine or paracrine functions (Baulieu, 1991). The 
circulating steroid hormones act both on peripheral target tissues and on the CNS, 
coordinating physiological and behavioral responses with specific biological purposes, e.g. 
reproduction. Thus, they influence the sexual differentiation of the genitalia and their 
functional state in adulthood, the development of secondary sexual characteristics, and 
sexual behavior. Unlike the lower mammals in which the ovaries and testes are the exclusive 
source of androgens and estrogens, in humans the adrenals cortex secretes large amount of 
inactive steroid precursors. These adrenal steroid precursors exert their functions in target 
tissues after conversion into active estrogens and/or androgens. This phenomenon which 
describes the conversion and action of steroid hormones within peripheral target tissues has 
been called “intracrinology” (Labrie, 1991, 2000).  
The rate of formation of each sex steroid hormone depends on the level of expression of the 
specific enzymes that synthesize androgens and estrogens in each cell of each tissue (Labrie 
et al., 1998; Stewart § Sheppard, 1992).  
The final step in the biosynthesis of active steroid hormones is catalyzed by members of the 
family of 17hydroxysteroid dehydrogenase (17HSD), which comprises different 
enzymes involved in steroidogenesis. 
2. 17hydroxysteroid dehydrogenases  
The 17-hydroxysteroid dehydrogenases (17-HSDs) belong to the short-chain 
dehydrogenase reductase (SDR) protein superfamily, which also includes the 3-
hydroxysteroid dehydrogenase (3HSD). These enzymes regulate the levels of bioactive 
steroid hormones in many tissues and they are expressed not only in genital tissues, which 
are the primary target, but also in peripheral blood. The 17-HSDs, along with other steroid 
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metabolizing enzymes such as aromatase, steroid sulfatase, 3-HSD and 5-reductase are 
able to produce their own hormones at the peripheral cells (intracrine activity). In 
steroidogenic tissues (the gonads and adrenal cortex) they catalyze the final step in 
androgens, estrogens and progesterone byosinthesis; in peripheral tissues, they convert 
active steroid hormones into their metabolites, and regulate hormone binding to their 
nuclear receptor. So far, 14 17HSDs have been characterized in mammals, which show 
little amino acid homology but that are all members of the SDR family, with the exception of 
17-HSD type 5 (17-HSD5) which is an aldo-keto reductase (Lukacik et al., 2006; Luu The, 
2001; Prehn et al., 2009). These isoenzymes differ as regards tissue-specific expression, 
catalytic activity, substrate and cofactors specificity (NAD/NADH vs NADP/NADPH), and 
subcellular localization (Payne § Hales, 2004). Although in vitro they act both as reductase or 
as oxidase enzymes, in vivo they work in a predominat one-way, or reductive or oxidative, 
converting inactive 17-ketosteroids in their active 17-hydroxy forms (Khan et al., 2004). 
Thus, they can be grouped into in vivo oxidative enzymes (17-HSD types 2, 4, 6, 8, 9, 10, 11 
and 14) and in vivo reductive enzymes (17-HSD types 1, 3, 5 and 7). 
2.1 Family members of 17-HSDs 
The main function of 17HSD type 1 (17HSD1), which has its highest concentration in 
the ovaries and placenta, is the catalytic reduction of estrone to estradiol (Luu The et al., 
1989). 17-HSD type 2 (17-HSD2) plays a major role in the inactivation of the sex steroid 
hormones by oxidizing estradiol and testosterone (T) to estrone and 4-Androstenedione 
(4-A), respectively (Wu et al., 1993), and has a broad tissue distribution (Casey et al., 1994). 
17-HSD type 3 (17-HSD3) plays a predominant role in male T production from 4-A 
(Geissler et al., 1994). Although this enzyme is found primarily in the testes, it is also present 
in adipose tissue, brain, sebaceous glands and bone. 17-HSD type 4 (17HSD4) is 
expressed in the liver (Adamski et al., 1996) and in the peroxisomes (Markus et al., 1995); 
this isoenzyme plays a major function in the metabolism of fatty acids, as has been described 
in murine models, while it has a minor role in the metabolism of steroids. In humans, 
mutations of the gene encoding for 17HSD4 isoenzyme lead to serious illness and death 
within the first year of life (Moller et al., 2001). 17-HSD type 5 (17HSD5), which is highly 
expressed in the testes, prostate, adrenals and liver, is believed to play a major role in the 
conversion of  4-A to T and therefore could explain the virilization obtained in patients 
affected with alterations of 17-HSD3. 17-HSD type 7 (17-HSD7) has been shown to play a 
role in metabolism of cholesterol (Marijanovic Z et al., 2003). 17HSD type 8 (17-HSD8) 
has been linked to a recessive form of polycystic kidney disease (Fomitcheva et al., 1998). 
Several of the 17HSD enzymes show overlap with enzymes involved in lipid metabolism 
(Tab.1).  
Since most of the 17-HSD enzymes are steroid metabolizing enzymes, they are possible 
drug targets in many cancers, such as breast and prostate cancer, as well as common 
diseases, such as obesity and metabolic syndrome. 
2.2 The role of 17-HSDs 
In a study conducted to observe the tissue-specificity of the transcriptional profiles of the 
17-HSDs, the expression of 17-HSDs type 1, 2, 3, 4, 5, 7 and 10 was observed both in the 
genital skin fibroblasts (both scrotal and foreskin) and in the peripheral blood, with the 
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Type of 17-HSD 
(Gene Name) 
Locations Functions Cofactor/ 
reactions 
Gene 
location 
17-HSD type 1 
(HSD17B1) 
liver, ovary, 
mammary glands 
and placenta 
catalyzes the 
interconversion of E1 to 
E2 
NADPH/ 
reduction 
 
17q21.2 
17-HSD type 2 
(HSD17B2) 
placenta, liver, 
intestine, 
endometrium, 
kidney, prostate, 
pancreas 
inactivates both E2 into 
E1 and T into 4-A 
NAD+/ 
oxidation 
16q23.3 
17-HSD type 3 
(HSD17B3) 
mainly testes, 
adipose tissue, 
brain, sebaceous 
glands and bone 
converts4-A to T NADPH/ 
reduction 
9q22.32 
17-HSD type 4 
(HSD17B4) 
liver, heart, 
prostate, testes, 
lung, skeletal 
muscle, kidney, 
pancreas, thymus, 
ovary,intestine, 
placenta and breast 
cancer lines 
inactivates both E2 into 
E1, and 5-diol into 
DHEA-; oxidation of 
FA 
NAD+/ 
oxidation 
5q23.1 
17-HSD type 5 
(AKR1C3) 
placenta, testes, 
prostate, adrenals 
and liver 
converts4-A to T in 
peripheral tissues; bile 
acid production and 
detoxification; 
eicosanoid synthesis 
NADPH/ 
reduction 
10p15.1 
17-HSD type 6 
(HSD17B6/RODH)
not determined only retinoid metabolism 
identified in humans 
NAD+/ 
oxidation 
12q13.3 
17-HSD type 7 
(HSD17B7) 
not determined cholesterol synthesis; 
catalyzes the 
interconversion of E1 to 
E2 
NADPH/ 
reduction 
10p11.2 
1q23 
17-HSD type 8 
(HSD17B8) 
widespread, liver, 
kidney, ovary, 
testes 
possible role in fatty acid 
metabolism; inactivates 
both E2 into E1 and 
androgens 
NAD+/ 
oxidation 
6p21.32 
17-HSD type 9 
(HSD17B8/RDH5) 
not determined only retinoid metabolism 
identified in humans 
not 
determine
d 
12q13.2 
17-HSD type 10 
(HSD17B10) 
widespread, liver, 
CNS, kidney, testes
oxidation of fatty acids; 
catalyzes the synthesis of 
DHT from 5-
androstane-3, 17diol; 
oxidation of the 21OH 
groups on C21 steroids 
NAD+/ 
oxidation 
Xp11.22 
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Type of 17-HSD 
(Gene Name) 
Locations Functions Cofactor/ 
reactions 
Gene 
location 
17-HSD type 11 
(HSD17B11) 
steroidogenic 
tissues, pancreas, 
liver, kidney, lung 
and heart 
converts 5-androstane-
3, 17diol to 
androsterone; lipid 
metabolism 
NAD+/ 
oxidation 
4q22.1 
17-HSD type 12 
(HSD17B12) 
not determined  fatty acid synthesis; 3-
ketoacyl-CoA reductase 
NADPH/ 
reduction 
11p11.2 
17-HSD type 13 
(HSD17B13) 
not determined enzymatically not 
characterized 
not 
determine
d 
4q22.1 
17-HSD type 14 
(HSD17B14) 
CNS, kidney inactivates both E2 into 
E1 and T into 4A; 
oxidation of FA 
NAD+/ 
oxidation 
19q13.33 
E 1 = Estrone; E2 = 17-estradiol; 5-diol = androst-5-ene 3 DHEA = dihydroepiandrosterone;  
NADPH/NADP+ = nicotinamide adenine di nucleotide phosphate;  
4-A = androstenedione; T = testosterone; 
FA = fatty acids 
Table 1. The different types of identified 17-HSD with corresponding locations and 
function  
exception of the 17-HSD-2 which was not seen in peripheral blood (Hoppe et al., 2006). All 
17-HSDs except 17HSD1 showed a significantly higher mRNA concentration in the 
foreskin compared to the scrotal tissue, demonstrating a tissue-specific local control of 
steroid hormone synthesis and action in addition to systemic effects (Hoppe et al., 2006). It 
has been demonstrated that the expression of 17-HSD5 increases with aging in scrotal skin 
fibroblasts and in peripheral blood mononuclear cells, while the 17-HSD3 mRNA 
expression is higher in the younger age subjects (Hammer et al., 2005; Hoppe et al., 2006). 
This implicates that 17-HSD3 has a more important role in childhood, which later is taken 
over by the 17-HSD5 after puberty.  
It was also demonstrated the existence of a large inter individual variability of the enzymatic 
transcription patterns (Hoppe et al., 2006). Microarray investigation of multiple blood 
samples taken on different days from the same individual showed time-dependent 
differences in gene clustering. The nature and extent of inter individual and temporal 
variation in gene expression patterns in specific cells and tissues is an important and 
relatively unexplored issue in human biology (Whitney et al., 2003). In light of such intra- 
and inter individual variability, basal and after stimulation levels of the steroid hormones 
can vary a within wide range in normal subjects. 
2.3 17-hydroxisteroid dehydrogenase type 3  
17-hydroxisteroid dehydrogenase type 3 (17-HSD3) isoenzyme catalyzes the reductive 
conversion of the inactive C-19 steroid, 4-A, into the biologically active androgen, T, in the 
Leydig cells of the testes (Payne § Hales, 2004). This protein shows a 23% sequence 
homology with the other 17-HSD isoenzymes, utilizes NAPDH as cofactor and it seems to 
be prevalently expressed in the fetal and adult testes. Extragonadal tissues such as bone, 
adipose tissue, sebaceous glands and brain have also been shown to express this enzyme 
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(Lukacik et al., 2006). It is encoded by HSD17B3 gene which maps to chromosome 9q22; it is 
60 kb in length and contains 11 exons. The cDNA encodes a protein of 310 amino-acids with 
a molecular mass of 34.5 kDa and no apparent membrane-spanning domain (Andersson et 
al., 1996).  
It has been demonstrated that HSD17B3 gene is constitutively suppressed and its 
transcription begins only upon removal of suppressors that act on the Alu repeat region 
located upstream of the translation site start of the gene promoter region (Xiaofei et al., 
2006).  
HSD17B3 gene alterations affecting the enzyme function have been associated with a rare 
form of 46,XY disorder of sexual development (DSD), termed 17-hydroxisteroid 
dehydrogenase deficiency (Geissler et al., 1994).  
3. Development of the male genitalia 
The development of the male internal and external genitalia in an XY fetus requires a 
complex interplay of many critical genes, enzymes and cofactors (Hannema § Hughes, 
2007). Wolffian ducts (mesonephric ducts) and mullerian ducts (paramesonephric ducts) are 
both present in early fetal life in the bipotential embryo. The wolffian ducts are the 
embryological structures that form the epididymis, vas deferens and seminal vesicles. T is 
produced by Leydig cells as early as 8 weeks of gestation and acts on the androgen receptor 
to stabilize the wolffian ducts (Tong et al., 1996). T and its 5-reduced end product, 
dihydrotestosterone (DHT), induce the formation of male external genitalia, including the 
urethra, prostate, penis and scrotum (Wilson, 1978). The mullerian ducts should regress in a 
male with the presence of the mullerian inhibiting substance produced by Sertoli cells in the 
testes. In addition, multiple other factors are necessary for the male phenotype to be 
congruent with a 46,XY genotype. The enzyme 17HSD3 is present almost exclusively in 
the testes and converts 4-A to T. The 5 -reductase type 2 enzyme is needed to convert T to 
DHT. In order for T and DHT to exert their androgenic role, there must be an intact 
androgen receptor. The lack of any one of these critical factors, including 17HSD3, can 
lead to a child with a DSD. 
3.1 Disorders of sexual development  
Disorders of sexual development (DSDs) are congenital conditions in which development of 
chromosomal, gonadal or anatomical sex is atypical (Houk et al., 2006; Hughes et al., 2006). 
These disorders are classified into three major categories: sex chromosome DSD, 46,XX DSD 
and 46,XY DSD. This designation was proposed to replace the former term of 
pseudohermaphroditism, according to the consensus statement on management of intersex 
disorders (Hughes et al., 2006). 46,XY DSD are a heterogeneous group of clinical conditions 
characterized by 46,XY karyotype, either normal or dysgenetic testes and female or 
ambiguous phenotype of external (and possibly internal) genitalia (Hughes et al., 2006). This 
disorder can have several etiologies, but more frequently is due to a disruption in androgen 
production and/or action. Defects in androgen action and metabolism include mutations in 
the androgen receptor gene (complete, partial or mild androgen insensivity syndrome-AIS 
and Kennedy syndrome), or in the steroid 5-reductase type 2 gene, encoding the enzyme 
which convert T into DHT in the uro-genital tract (Quigley et al., 1995; Wilson et al., 1993). 
Instead, disorders of androgens biosynthesis are rare and usually due to alteration of 
enzyme involved in the conversion of cholesterol to T, such as the steroidogenic acute 
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regulatory (stAR) protein, the steroidogenic enzyme P450ssc, 3HDS type 2, 
17hydroxylase/17-20 lyase and 17ǃ-hydroxysteroid dehydrogenase type 3 (17-HSD3) 
(Gobinet et al., 2002; Miller et al., 2005), (Fig.1)  
 
 
Fig. 1. Steroidogenic pathway and role of 17- HSD3 
4. 17β-hydroxysteroid dehydrogenase type 3 deficiency 
17ǃ-hydroxysteroid dehydrogenase type 3 (17ǃ-HSD3) deficiency (OMIM #264300), 
originally described as 17-ketosteroid reductase deficiency (Saez et al., 1971), is an 
autosomal recessive disorder which represents the most common defect of the biosynthesis 
of T in 46,XY DSD (Bertelloni et al., 2004; Mendonca et al., 2000). This disorder is due to an 
impaired conversion of Δ4-A into T in the testes (Bertelloni et al., 2009; Faienza et al., 2008). 
Deficiency in the 17-HSD3 enzyme can be caused by either homozygous or compound 
heterozygous mutations in the HSD17B3 gene (Geissler et al., 1994). Mutations in the 
HSD17B3 gene confer a spectrum of 46,XY disorders of sexual organ development ranging 
from completely undervirilized external female genitalia (Sinnecker type 5), predominantly 
female (Sinnecker type 4), ambiguous (Sinnecker type 3), to predominantly male with 
micropenis and hypospadias (Sinnecker type 2) (Boehmer et al., 1999; Sinnecker et al., 1996). 
The most frequent presentation of 17ǃ-HSD3 deficiency is a 46,XY individual with female 
external genitalia, labial fusion and a blind ending vagina, with or without clitoromegaly 
(Sinnecker types 5 and 4).  
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4.1 Epidemiology and demographic 
The DSD affect 1 in 5,000 to 5,500 people (0.018%) (Parisi et al., 2007; Thyen et al., 2006). 
Although the precise incidence of 17ǃ-HSD3 deficiency is unknown, a nation-wide survey in 
the Netherlands showed a minimal incidence of 17ǃ-HSD3 deficiency of about 1:147.000 
newborns, with a frequency of heterozygotes of 1 in 135 (Boehmer et al., 1999). The 
frequency of complete androgen insensitivity syndrome (CAIS) from the same population 
was 1 in 99,000, which indicates that the frequency of 17-HSD3 deficiency is 0.65 times that 
of CAIS (Boehmer et al., 1999). 17-HSD3 deficiency is rare in Western countries, whereas in 
areas of high consanguinity, such as among the Gaza Strip Arab population, the incidence of 
17-HSD3 deficiency has been reported to be 1 in 100–300 people (Rosler et al., 1996, 2006). 
Of the known cases of 17-HSD3 deficiency, most of the patients have been reported in 
Europe, Asia, Australia and South America, whereas only 11 cases have been reported in the 
United States (Mains et al., 2008; Moeller § Adamski, 2009). In a recent study from a gender 
assessment team in the United States that looked at DSD over a 25-year period, no patient 
with 17-HSD3 deficiency was diagnosed (Paris et al., 2007). Moreover, in the United 
Kingdom DSD database, patients with 17ǃ-HSD3 represent about the 4% of the total 46,XY 
DSD subjects (13/322) (Hughes, 2008). Probably the rate of 17-HSD3 deficiency in the 
United States is not so low, but many cases are misdiagnosed. In one study, patients who 
were later confirmed to have 17-HSD3 deficiency were initially misdiagnosed with AIS, 
and the rate of misdiagnosis was calculated to be 67% (Faisal et al., 2000). The risk of 
misdiagnosis is especially problematic because the clinical findings in 17-HSD3 deficiency 
may mimic AIS in childhood and 5-reductase deficiency in puberty (Lee et al., 2007). Thus, 
correct diagnosis should be made early so that treatment, management and genetic 
counseling can be specifically directed toward 17-HSD3 deficiency (Hiort et al., 2003; 
Johannsen et al., 2006). 
4.2 Clinical features 
The characteristic phenotype of 17-HSD3 deficiency is a 46,XY individual with testes and 
male wolffian-duct derived urogenital structure (e.g. epydidymus, vas deferens and 
seminals vesicles), but with undervirilization of the external genitalia. Patients show a 
phenotypic variability ranging from undervirilization of the external genitalia with or 
without clitoromegaly and/or labial fusion, to complete female external genitalia and a 
blind-ending vagina; testes may be situated in the abdomen or in the inguinal channels or in 
the labia majora (Grumbach et al., 1998). Gynecomastia, likely as consequence of high 4-A 
levels and its conversion to estrogens in peripheral tissues, is not usually present 
(Andersson et al, 1996; Balducci et al., 1985; Mendonca et al., 2000). Two late-onset variants 
of uncertain pathophysiology, one of which is characterized by gynecomastia in boys 
(Rogers et al., 1985; Castro-Magana et al., 1993) and the other by polycystic disease in 
woman have been described (Pang et al., 1987). 
4.2.1 Birth 
Patients with mutations in the HSD17B3 gene may go unnoticed at birth as they commonly 
have female external genitalia (Balducci et al., 1985; Lee et al., 2007; Rosler et al., 1996). These 
children are usually assigned the female gender and grow up as such, and the diagnosis 
may be missed until adolescence (Andersson et al., 1996; Balducci et al., 1985; Bohmer et al., 
1999; Faienza et al., 2007; Lee et al., 2007; Mendonca et al., 2000; Rosler et al., 2006).  
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Those subjects who come to medical attention in childhood have some degree of virilization 
or inguinal hernia with testes present along the inguinal canals or labioscrotal folds 
(Andersson et al., 1996; Bohmer et al., 1999; Lee et al., 2007). Less often patients have 
ambiguous external genitalia (Can et al., 1998; Eckstein et al., 1989), male genitalia with a 
micropenis (Ulloa-Aguirre et al., 1985) or hypospadias (Andersson et al., 1996). In these 
patients, the male sex is assigned at birth and they are raised accordingly (Rosler et al., 
1996).  
The degree of virilization can vary from Sinnecker stage 5 to stage 2 as mentioned above. 
This is speculated to be due to the partial activity of 17-HSD3 in the testes and 
extratesticular T conversion by other members of the family, such as 17-HSD5 (Lee et al., 
2007; Qiu et al., 2004).  
On examination, a separate urethral and vaginal opening is noted in many subjects, 
although a short urogenital sinus is reported in some (Bertelloni et al., 2006; Lee et al, 2007). 
Blind ending vagina that have length ranging from 1 to 7 cm has been reported in this 
condition (Faienza et al., 2007; Mendonca et al., 2000).  
Although these findings are not specific for 17-HSD-3 deficiency and can be seen in other 
46,XY DSD, they should raise suspicion for 17 HSD3 deficiency. 
4.2.2 Pubertal 
At the time of puberty, patients initially reared as females who have not undergone 
gonadectomy  may have primary amenorrhea and varying degrees of virilization, including 
development of male body habitus, increased body hair and deepening of the voice (Faienza 
et al., 2007; Lee et al., 2007; Mains et al., 2008; Mendonca et al., 2000; Rosler et al., 1992; 
Rosler et al., 1996;). The clitoris can enlarge to as much as 5–8 cm in length due to peripheral 
conversion of T (Balducci et al., 1985; Mendonca et al., 2000;), but still remains smaller than a 
normal-sized penis and may be affected by chordee (Farkas § Rosler, 1993).  
The paradox of the failure of intrauterine virilization but virilization in puberty remains an 
enigma not fully explained.  A limited capacity of the extragonadal tissues to convert 4-A 
to T in embryonic life might explain the lack of virilization at birth (Ulloa-Aguirre et al., 
1985). This might then be overcome at puberty, when the levels of 4-A are more elevated 
and thus activate the peripheral conversion into T. It has been demonstrated that in these 
subjects more than 90% of circulating T derives from peripheral conversion of 4-A into T 
by other isoenzymes (Andersson et al., 1996; Goebelsmann et al.,1973). There is abundant 
evidence of the presence of 17-HSDs and other enzymes involved in androgen formation in 
a large series of human tissues, particularly liver, skin and adipose tissue (Martel et al., 
1992). 
This extragonadal activity is presumable under different genetic control (17-HSD type 1, 2 
or 5 encoding gene) which is apparently unimpaired in these patients (Andersson et al., 
1996; Luu-The et al., 1989).  
Moreover, there seems to be a correlation between the type of mutation and the percentage 
of enzyme inactivation. There are several  reports showing a residual enzymatic activity (15-
20%) in cultured mammalian cells carrying the R80Q mutation, after several hours of 
incubation with the substrate (androstenedione). On the contrary, most missense mutations 
seems to severely impair the enzyme activity (Andersson et al., 1996; Geissler et al., 1994;).  
A late onset form of 17-HSD3 deficiency causing breast development was reported in up 
to 6% of the patients with idiopathic pubertal gynecomastia (Castro-Magana et al., 1993). 
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It appeared to be related to the functional inactivity of 17-HSD3 during puberty and 
increased aromatization of 4-A to produce excessive estrogens; however, the HSD17B3 
gene was not studied for defects in this study (Balducci et al., 1985; Bertelloni et al., 
2009b).  
4.2.3 Prenatal 
Recently, the first case of prenatally identified 17-HSD3 deficiency was reported in a child 
with discordance between 46,XY karyotype and female external genitalia with phallic 
structure (Bertelloni et al., 2009b).  
4.3 Endocrine findings 
The phenotype of 17-HSD3 deficiency is clinically indistinguishable from that of AIS or 
5-reductase 2 deficiency. In fact, the majority of the subjects had a misdiagnosis of AIS or 
5ǂ-reductase deficiency before adequate assessment, and these two latter DSD represent the 
principal differential diagnoses in infancy and adolescence, respectively (Balducci et al., 
1985; Bertelloni et al., 2009a; Lee et al., 2007) (Fig. 2).  17-HSD3 however, can be reliably 
diagnosed by systematic endocrine evaluation (Fig. 2) and the diagnosis confirmed by 
molecular genetics study.  
The characteristic hormonal profile of 17-HSD3 deficiency is of increased concentrations of 
4-A and reduced levels of T (Faisal et al., 2000). In particular, a diagnostic hallmark of 17-
HSD3 deficiency is a decreased serum T/4-A ratio (<0.8-0.9) after human corionic 
gonadotropin (hCG) stimulation in prepubertal subjects, while baseline values seems to be 
informative in early infancy and adolescence (Rosler et al., 1996). A normal ratio above 0.8 
after hCG stimulation raises the suspicion of other diagnoses such as androgen receptor 
mutation. An elevated T/DHT raises the suspicion of a 5-reductase type 2 deficiency. 
However, low basal T/4-A ratio is not specific for 17-HSD3 deficiency, being sometimes 
also found in patients with other defects in T synthesis or with Leydig cell hypoplasia. The 
clinical phenotype of Leydig cell hypoplasia may also resemble that of 17ǃ-HSD3 deficiency 
before puberty, but the absence of all testicular androgens (baseline and after hCG 
stimulation) and the lack of pubertal development or isosexual pubertal arrest should allow 
to differentiate between them (Bertelloni et al., 2009a).  
A diagnostic tool could be represented by the urinary ketosteroid analysis performed by 
means gas chromatography tandem mass spectrometry, a high sensitive technique for the 
detection of anabolic steroid residues in urine (Van Poucke et al., 2005).  
The DHT levels in 17- HSD-3 deficiency can be decreased, normal or high, while the 
dehydroepiandrosterone (DHEA) levels are typically high (Mendonca et al., 2000).   
Elevated serum LH and FSH levels at baseline and after GnRH test administration, 
indicating the impairment of the pituitary regulatory control by gonadal hormones, have 
been found in these subjects (Mendonca et al., 2000). Increased serum LH causes elevated 
4-A levels, allowing the formation of some T either in extra glandular tissues or in the 
testes, when some residual enzyme activity is present (Andersson et al., 1996). Elevation of 
FSH  may also be due to a damage to the spermatogenic tubules as a result of long term 
cryptorchidism as documented in histological specimens from adult subjects. However, FSH 
levels have been reported to be normal in some subjects (Van Poucke et al., 2005; Rosler et 
al., 1992). 
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Fig. 2. A diagnostic algorithm to elucidate the various etiologies of 46,XY DSD. The diagram 
shows the importance of hCG stimulation in the diagnosis of 46,XY DSD. Upon hCG 
stimulation, if the T/4-A ratio is >0.8, the diagnosis of 17- HSD3 can be suspected; if the 
T/DHT ratio is >20, a diagnosis of 5-reductase deficiency can be suspected. If the response 
of T is >100 ng/dl, androgen insensivity syndrome (AIS) is possible. However, if the 
response is <100 ng/dl, causes of gonadal dysgenesis should be sought. Once a diagnosis is 
suspected, molecular genetic studies can be used for definitive diagnosis. 
4.4 Molecular diagnosis 
HSD17B3 gene alterations have been identified in patients showing clinical and biochemical 
characteristics of 17ǃ-HSD3 deficiency. The disease is genetically heterogeneous and 
genotype-phenotype correlations have not been found.  
To date, 27 mutations in the HSD17B3 gene have been reported. These include intronic 
splice junction abnormalities, exonic deletions and missense mutations (Table 2) (Mains et 
al., 2008). The majority are missense mutations inherited as homozygous or compound 
heterozygous mutations, occurring most frequent in exons 3,9,10 of the gene; 4 are splice 
junction abnormalities (Andersson et al., 1996; Boehmer et al., 1999), 1 is a small deletion 
(777-783), and 1 is a thymidine deletion resulting in a frame shift mutation which alters the 
amino acid sequence from codon position 187 onward with a premature termination in 
codon 226 (Boehmer et al., 1999; Twesten et al., 2000).  
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Age of 
diagnosis 
Phenotype 
Clinical presentation 
Ethnicity Mutation Mutation 
type 
Effect 
Reference 
16 years  46,XY DSD;  
hirsutism, 
clitoromegaly, 
failure to menstruate 
Iranian p.Ser65Leu missense/ 
inactivates 
enzyme 
Andersson et al., 
1996 
6 months, 
11 years 
46,XY DSD;  
female prepubertal 
external genitalia, pubertal 
virilization, severe hair 
growth, voice changes and 
clitoral enlargement (6 
months, child diagnosed 
because of family history) 
South 
Asian 
p.Ala56Thr missense/ 
severe 
impairment 
of enzyme 
Lee et al., 2007 
Moghrabi et al., 1998 
4–16 years 46,XY DSD;  
ambiguous genitalia, 
pubertal virilization 
Dutch p.Asn74Thr missense Boehmer et al., 1999 
4–43 years 46,XY DSD;  
ambiguous genitalia at 
birth to mild 
clitoromegaly, pubertal 
virilization, male gender 
role, and many reassigned 
as males if raised as girls 
Arab, 
Dutch, 
Brazilian, 
Portuguese 
p.Arg80Gln missense/ 
impaired 
enzyme 
activity 
(NADPH 
binding site)
Mendonca et al., 
2000 Geissler et al., 
1994 Boehmer et al., 
1999 Roesler et al., 
1996  
Roesler et al., 1992  
Mendonca et al., 
1999 
Newborn– 
12 years 
46,XY DSD;  
female external genitalia, 
palpable gonads, clitoral 
enlargement and 
virilization at puberty 
Spanish, 
Italian, 
Lebanese 
p.Arg80Trp 
 
missense/ 
complete loss 
of enzyme 
activity 
(NADPH 
binding site) 
McKeever et al., 
2002 Faienza et al., 
2007 
Bilbao et al., 1998 
4 months– 
15 years 
46,XY DSD;  
pubertal virilization, mild 
clitoromegaly, voice 
changes 
English, 
German 
c.325+4,A-T splice 
junction/ 
disrupts 
splice 
acceptor site
Mendonca et al., 
2000 
Boehmer et al., 1999 
Andersson et al., 
1996 
8, 23, 34 
years 
15 years  
 
46,XY DSD;  
inguinal hernia, failure of 
breast development, facial 
and body hair growth, 
voice changes, clitoral 
enlargement 
Dutch, 
Brazilian 
c.326–1,G-C splice 
junction 
Mendonca et al., 2000 
Geissler et al., 1994 
Boehmer et al., 1999 
Andersson et al., 
1996 
Mendonca et al., 
1999 Moghrabi et al., 
1998 
14,15 years 46,XY DSD; pubertal 
virilization, mild 
clitoromegaly, voice 
changes 
English, 
German 
p.Asn130Ser missense/ 
severe 
impairment 
of enzyme 
activity 
Lee et al., 2007 
Bertelloni et al., 2009 
Moghrabi et al., 1998 
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Unknown 46,XY DSD  unknown c.538–1,G-A splice 
junction 
Mueller § Coovadia, 
2009 
13 years 46,XY DSD; 
clitoromegaly and 
coarsening of voice, 
scrotalization of labia 
majora and inguinal 
masses 
American 
(Italian, 
German, 
Irish) 
p.Gln176Pro missense Andersson et al., 
1996 
Moghrabi et al., 1998 
12 years 46,XY DSD;  
female prepubertal 
development, clitoral 
enlargement at 12 years of 
age, testes in inguinal 
canal 
German  c.608delT downstream 
premature 
stop codon 
Twesten et al., 2000 
10 years 46,XY DSD; 
prepubertal female 
external genitalia, inguinal 
mass 
Turkish p.Ala188Val missense/ 
inactivates 
enzyme 
Boehmer et al., 1999 
12 years 46,XY DSD;  
pubertal virilization, facial 
hair, 4–8 cm phallus and 
labioscrotal folds 
Afghan p.Met197Lys missense/ 
alters 
secondary 
protein 
structure 
Lee et al., 2007 
10,16,17 
years 
46,XY DSD;  
prepubertal female 
external genitalia, pubertal 
virilization, male gender 
rol 
Syrian, 
Turkish, 
Dutch, 
Greek-
American 
c.655–1,G-A splice 
junction/ 
disrupts 
splice 
acceptance 
site 
Geissler et al., 1994 
Boehmer et al., 1999 
Andersson et al., 
1996  
Moghrabi et al., 1998 
Ademola Akesode 
et al., 1977 
13, 18, 21, 
26 years 
46,XY DSD;  
absence of menses, failure 
of breast development, 
facial and chest hair and 
clitoral enlargement, male 
and female 
gender identity in siblings
African-
Brazilian, 
Italian 
p.Ala203Val missense/ 
inactivates 
enzyme 
Mendonca et al., 
2000 
Geissler et al., 1994 
Mendonca et al., 
1999 Moghrabi et al., 
1998  
Unknown 46,XY DSD;  
pubertal virilization  
Southern 
Italian 
p.Ala203Glu missense Mendonca et al., 
2000 
Bertelloni et al., 2009 
Newborn, 
20 years 
46,XY DSD;  
prepubertal female 
externalgenitalia to 
perineoscrotal 
hypospadias, primary 
amenorrhea, mild 
clitoromegaly 
White 
American,
English 
p.Val205Glu missense/ 
inactivates 
enzyme 
Lee et al., 2007 
Andersson et al., 
1996 
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Newborn 
 
46,XY DSD;  
ambiguous genitalia, 
clitoromegaly (1.5 cm) and 
posterior fusion and 
scrotalization of the labia 
majora which contained 
palpable masses 
German  p.Phe208Ile missense/ 
inactivates 
enzyme 
Andersson et al., 
1996 
2 years, 
3 months 
46,XY DSD;  
inguinal mass, mild 
clitoromegaly 
Italian  p.Leu212Gln missense/ 
inactivates 
enzyme 
Geissler et al., 1994 
Bertelloni et al., 2006 
14, 15, 21 
years 
 
46,XY DSD; 
female or ambiguous 
genitalia at birth, male 
behaviors in childhood, 
pubertal virilization, 
absence of menses, male 
gender role 
White 
Brazilian, 
English 
p.Glu215Asp missense/ 
inactivates 
enzyme 
Mendonca et al., 
2000 
Lee et al., 2007 
Andersson et 
al.,1996 
2 months, 2, 
6, 
17 years  
46,XY DSD; 
 clitoromegaly, primary 
amenorrhea, absent labia 
minora, severe 
hypospadias with 
undermasculinization–
raised as males and 
females 
African-
American, 
South 
Asian 
p.Ser232Leu missense/ 
inactivates 
enzyme 
Geissler et al.,1994 
Lee et al., 2007 
Moghrabi et al., 1998 
 
17 years  
 
46,XY DSD;  
clitoromegaly, primary 
amenorrhea, inguinal 
masses 
African-
American, 
Italian 
p.Met235Val missense/ 
inactivates 
enzyme 
Geissler et al.,1994 
Bertelloni et al., 2006 
Moghrabi et al., 1998 
15 years 46,XY DSD; 
testes in herniorrhaphy 
sac, failure to menstruate 
Polish  c.777-
783delGAT
AACC 
deletion/ 
frame shift 
truncates 
protein 
Andersson et 
al.,1996 
 
5, 18 
months, 
2–4 years 
46,XY DSD;  
prominent clitoris, 
palpable 
inguinal gonads 
Pakistani p.Cys268YT
yr 
missense/ 
inactivates 
enzyme 
Lee et al., 2007 
Lindqvist et al., 2001 
Unknown 46,XY DSD  French p.His271Arg missense/ 
inactivates 
enzyme 
Bachelot et al., 2006 
12, 14 years 46,XY DSD;  
clitoromegaly, failure of 
breast development and 
deepening of voice 
White 
American, 
Dutch 
p.Pro282Leu missense/ 
inactivates 
enzyme 
Boehmer et al., 1999 
Andersson et 
al.,1996 
6 months 46,XY DSD;  
normal female prepubertal 
genitalia, bilateral inguinal 
hernia at sonography 
Italian, 
West 
Indian  
p.Gly289Ser polymorphism
/ 
unknown 
Boehmer et al., 1999 
Bertelloni et al., 2009 
Table 2. Mutations reported to date in patients with 17-HSD3 deficiency phenotype 
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Two missense mutations, the 239 G to A resulting in an Arg to Gln (R80Q) substitution, 
which is the most frequent alteration described in the Arab population living in the Gaza 
Strip (Boehmer et al.,1999; Mains et al., 2008; Rosler et al., 1996), and the 238 C to T resulting 
in an Arg to Trp (R80W) substitution (Bilbao et al, 1998; Faienza et al., 2007) involve the 
same arginine residue in exon 3 at position 80. This site has been extensively studied by 
systematic replacement of the wild-type arginine at position 80 and has been shown to be 
extremely important for both forming the salt bridge with the terminal phosphate moiety of 
the NADPH, as well as providing for a hydrophobic pocket for the purine ring of the 
adenosine portion of the NADPH (McKeever et al., 2002). Thus, this arginin is critical for 
cofactor binding and the substitution by different amino acids results in alteration of 
cofactor preference, switching from NADPH to NADH (Payne § Hales, 2004).  
One polymorphic substitution (G289S) has been described in a heterozygous form in 
apparently normal individuals. This polymorphism does not impair the kinetic properties of 
the normal enzyme (Moghrabi et al., 1998). A possible role of the G289S variation has been 
demonstrate in prostate cancer (Margiotti et al., 2002).  
Most gene alterations severely compromise the enzyme activity, but the R80Q mutation 
results in a 17-HSD3 residual enzyme activity (20%), showing a significantly lower reaction 
velocity as compared to the normal enzyme (Geissler et al., 1994). 
4.5 Worldwide distribution of ancient and de novo mutations 
Haplotype analysis of genetic markers flanking the HSD17B3 gene has been performed to 
establish the ancient or de  novo occurrence of mutations described in European, North 
American, Latin American, Australian and Arab populations (Boehmer et al., 1999). Dutch, 
German, white Australian and white American patients carrying the 325+4,A –T mutation 
share the same genetic markers and seem to have a common European ancestor. A founder 
effect was also demonstrated for the R80Q mutation that is common in Dutch, Arab (in 
Gaza), white Brazilian, and white Portuguese patients. As this mutation is associated with a 
specific haplotype, a common ancestor introduced during the Phoenician migration has 
been hypothesized (Rosler et al., 2006). An additional founder effect has been suggested for 
655–1,G-T mutation found in Greeks, Turks and Syrians patients that may have spread to 
the Mediterranean area during Ottoman Empire (Boehmer et al., 1999). On the contrary, 
patients harboring the 326-1,G-C and the c.Pro282Leu mutations have a different marker 
genotype suggesting that these are the novo mutations (Boehmer et al., 1999). 
4.6 Genotype-phenotype correlation 
No phenotype-genotype correlation has been noted in 17-HSD3 deficiency, as exemplified 
by members of the same family who have different phenotypes despite the same genotype 
(Lee et al., 2007). A variable T/4-A ratio after human chorionic gonadotropin (hCG) 
stimulation was also seen despite the same homozygous mutation in different subjects of 
the same pedigree. This can be attributed to the extratesticular ability of some subjects to 
convert 4-A to T by other enzymes such as 17-HSD5 (Qiu et al., 2004). 
4.7 Imaging studies 
Imaging studies that reveal the absence of mullerian structures and persistent wolffian 
structures also point to the diagnosis of 17-HSD3 deficiency, but this is not pathognomonic 
as 5-reductase type 2 deficiency will also have similar findings. Histological evidence from 
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gonadal tissue may show normal testicular structures, which can help to exclude any 
structural abnormalities (testicular dysgenesis) as the cause for the 46,XY DSD. Despite an 
early orchidopexy, an absent spermatogenesis has been seen in patients affected with 17-
HSD3 deficiency raised as males (Dumic et al., 1985). So far, no patient with 17-HSD3 
deficiency was fertile although raised as male, thus infertility appears to be the rule in 
adulthood (Tab. 3) (Bertelloni et al., 2009a; Rosler et al., 1996). 
 
Patients Epididimus Testes 
mla   SDS 
Spematogonia
cells 
Sertoli 
cells 
Leydig Micro-
calcifications 
1 Yes 1.4   –1.0 Scarce Normal Normal No 
2 Yes 1.0   –0.5 Present  
(sub-normal) 
Normal Normal Yes 
3 Yes 2.0     2.0 Present Normal Normal No 
4 Yes 9.0     1.3 Absent/ 
very scarce 
Normal Hypertrophic No 
a mean of the two gonads; SDS: SD score.  
Normal values from Cassorla et al., 1981 for patients 1-3 and from Taranger et al., 1976  for patient 4. 
Table 3. Gonadal findings in 4 subjects with 17ǃ-HSD3 deficiency  
4.8 Gender behavior 
In the absence of a correct diagnosis before puberty, most patients with 17-HSD deficiency 
are raised as females and undergo virilization during adolescence due to extratesticular 
conversion of 4-A to T, secondary to some residual function of the enzyme and increased 
substrate availability in 4-A at puberty (Andersson et al., 1996). In cases with partial 
virilization, early post-natal diagnosis and consequence successful androgen treatment may 
result in a male sex assignment and in a nearly normal male phenotype in adulthood.  
Gonadectomy is recommended before puberty for those individuals who have been raised 
as females and wish to remain so. In these subjects, female sex characteristics should be 
induced or maintained with appropriate hormone replacement therapy  (Hiort et al., 2003). 
Vaginal dilation using the modified Frank’s procedure or vaginal reconstruction surgery 
may be necessary to create a vaginal cavity with adequate capacity for sexual relations 
(Castro-Magana et al., 1993). The patient and family will need appropriate psychological 
counseling to accept the diagnosis and the infertility that accompanies it (Gooren, 2002). In 
patients with a male attitude, it is possible to achieve adequate male development without 
medical intervention, when corrective surgery has been judged to be warranted (Boehmer et 
al., 1999; Farkas § Rosler, 1993; Rosler et al., 1996). Exogenous T treatment does not seem to 
yield additional benefits in adulthood (Mendonca et al., 2000; Farkas § Rosler, 1993), while 
pre-operative T administration may result in a better cosmetic appearance of the external 
genitalia (Farkas § Rosler., 1993). Gender role changes have been reported in 39-60% of cases 
of 17-HSD3 deficiency who have been raised as girls (Wilson, 1999). Genetic and endocrine 
evidence indicates that androgens play an important role in male gender behavior and 
identity. However the fact that many individuals with mutations of the 5-reductase and 
17-HSD3 encoding genes do not change their gender role behavior implies that other 
www.intechopen.com
 
Steroids – Basic Science 
 
134 
factors (social, psychological or biological) contribute to modulating human sexual behavior. 
Because gender-appropriate rearing, and not the chromosomal, gonadal or genital factors 
plays a crucial role in gender identity development, early diagnosis and treatment if patients 
with the 17-HSD3 deficiency is very important. 
4.9 Psychological aspects 
Sex assignment of children with DSD is a subject of intense debate. The early pioneers in this 
field coined the term ‘optimal gender policy’, which advocated for early corrective surgery 
to help the affected children and their parents to facilitate stable gender identity and 
appropriate gender role behavior (Money et al., 1955) . Opponents of early surgery argue for 
a ‘full consent policy’, in which surgery is not performed in non-emergency situations 
before full consent may be obtained from the child (Kipnis § Diamond, 1998). In 17-HSD3 
deficiency, as in all situations characterized by severe undervirilization (Sinnecker stage 5 or 
4), is not always feasible to wait the start of the virilization and/or the age for a reliable full 
consent for major intervention, because in this waiting period the patient could assume a 
female gender role and identity. According to the recent guidelines regarding ethical 
principles and recommendations for the medical management of DSD in children and 
adolescents, the parents take the first-line responsibility in defining what might be best for 
the child, and this might vary according to their individual experience and lifestyle, cultural 
expectations and religious beliefs (Wiesemann et al., 2010). The child, according to his or her 
developmental level, can express own preference. Each case must be weighed on its own 
merits. When there is a doubt, the psychological and social support of the child and the 
parent is to be ranked higher than the creation of biological normalcy.  
4.10 Malignancy risk 
The external genitalia are mostly female in 17-HSD3 deficiency, but the internal structures 
are derivatives of wolffian structures. The testes are usually positioned in the inguinal canal, 
sometimes at the labia majora and rarely in the abdominal cavity (Mendonca et al., 2000). 
The consensus statement for management of DSD puts the risk of germ cell malignancy at 
28% in 17-HSD3 deficiency (Houk et al., 2006; Hughes et al., 2006). This puts it in the 
intermediate risk group for malignancies and close monitoring is recommended for 
someone who is raised as a male rather than having gonadectomy at the time of diagnosis. 
5. Conclusions 
Diagnosis and consequently early treatment of the 17-HSD3 deficiency is frequently 
difficult because clinical signs are often mild or absent from birth until puberty. Moreover, 
the 17-HSD3 deficiency is clinically indistinguishable from other forms of 46,XY DSD such 
as AIS or 5-reductase 2 gene deficiency. The correct diagnosis can be arrived at by 
systematic endocrine evaluation and, most importantly, by the calculation of the T/4-A 
ratio. The diagnostic power of biochemical parameters is not always specific, because no 
normal reference range has yet been established in strictly age-matched controls and 
because of overlapping with other causes of 46,XY DSD due to impaired T biosynthesis. 
Molecular genetic testing confirms the diagnosis and provides the orientation for genetic 
counseling. A high index of suspicion should be present for any female who presents with 
inguinal hernias or mild clitoromegaly in infancy or early childhood. The virilization in the 
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adolescent girl should also arouse suspicion. Since there are unique clinical implications 
based on the diagnosis of this condition, it is important to be as prompt and accurate as 
possible. In conclusion, endocrine evaluation is an important tool for the selection of 
patients with a suspected 17-HSD3 deficiency. In these patients, mutational analysis of the 
HSD17B3 gene, supported by a knowledge of the ethnic distribution  of mutations, is 
irreplaceable in confirming the diagnosis. 
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